115 related articles for article (PubMed ID: 23465239)
1. Soluble fibrin monomer complex levels during oral anticoagulant therapy do not predict subsequent thromboembolic events in patients with permanent atrial fibrillation.
Sadanaga T; Mitamura H
Int J Cardiol; 2013 Sep; 168(1):578-80. PubMed ID: 23465239
[No Abstract] [Full Text] [Related]
2. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy.
Sadanaga T; Kohsaka S; Ogawa S
Cardiology; 2010; 117(1):31-6. PubMed ID: 20881392
[TBL] [Abstract][Full Text] [Related]
3. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.
Sadanaga T; Sadanaga M; Ogawa S
J Am Coll Cardiol; 2010 May; 55(20):2225-31. PubMed ID: 20466203
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.
Rivera-Caravaca JM; Roldán V; Romera M; Esteve-Pastor MA; Valdés M; Lip GYH; Vicente V; Marín F
J Gen Intern Med; 2018 Jun; 33(6):847-854. PubMed ID: 29569024
[TBL] [Abstract][Full Text] [Related]
5. Fibrin D-dimer levels and thromboembolic events in patients with atrial fibrillation.
Watson T; Shantsila E; Lip GY
Int J Cardiol; 2007 Aug; 120(1):123-4; author reply 125-6. PubMed ID: 17055595
[No Abstract] [Full Text] [Related]
6. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.
Ansell J
Circulation; 2012 Jan; 125(1):165-70; discussion 170. PubMed ID: 22215891
[No Abstract] [Full Text] [Related]
7. Recent advances in oral anticoagulation for atrial fibrillation.
Singh M; Adigopula S; Patel P; Kiran K; Khosla S
Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):395-407. PubMed ID: 20965952
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant therapy is prescribed less often in paroxysmal atrial fibrillation regardless of thromboembolic risk: results from the Registry of Atrial Fibrillation To Investigate New Guidelines (RAFTING).
Pipilis A; Farmakis D; Kaliambakos S; Antoniou A; Goudevenos J; Lekakis J;
Int J Cardiol; 2014 Aug; 175(3):569-70. PubMed ID: 24874899
[No Abstract] [Full Text] [Related]
9. D-dimer level influences thromboembolic events in patients with atrial fibrillation.
Nozawa T; Inoue H; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
Int J Cardiol; 2006 Apr; 109(1):59-65. PubMed ID: 15992948
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral anticoagulant therapy on fibrinolysis parameters in chronic non-rheumatic atrial fibrillation.
Roldán-Schilling V; Marín-Ortuño F; Marco-Vera P; Sogorb-Garri F
Haematologica; 2000 Jul; 85(7):778-80. PubMed ID: 10897143
[No Abstract] [Full Text] [Related]
11. Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Acharjee S; Cannon CP
Crit Pathw Cardiol; 2011 Jun; 10(2):84-6. PubMed ID: 21988948
[TBL] [Abstract][Full Text] [Related]
12. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients.
Torn M; Cannegieter SC; Bollen WL; van der Meer FJ; van der Wall EE; Rosendaal FR
Arch Intern Med; 2009 Jul; 169(13):1203-9. PubMed ID: 19597069
[TBL] [Abstract][Full Text] [Related]
13. [Anticoagulation in pregnancy and post partum in heat valve diseases, thrombosis or atrial fibrillation: fetal risk versus maternal thromboembolism].
Gohlke-Bärwolf C
Z Kardiol; 2001; 90 Suppl 4():49-56. PubMed ID: 11373944
[TBL] [Abstract][Full Text] [Related]
14. [Predictive value of coagulative molecular markers for thromboembolism in patients with nonvalvular atrial fibrillation: prospective five-year follow-up study].
Enta K; Iwade K; Aosaki M; Uchida T; Kasanuki H
J Cardiol; 2004 Dec; 44(6):223-32. PubMed ID: 15638220
[TBL] [Abstract][Full Text] [Related]
15. Once atrial fibrillation, always oral anticoagulation?
Verheugt FW
Thromb Res; 2007; 119(3):275-6. PubMed ID: 16426666
[No Abstract] [Full Text] [Related]
16. Use of anticoagulants in elderly patients.
Bauersachs RM
Thromb Res; 2012 Feb; 129(2):107-15. PubMed ID: 22014849
[TBL] [Abstract][Full Text] [Related]
17. Tests of fibrin metabolism in recurrent venous thromboembolism.
Bynum LJ; Parkey RW; Wilson JE
Arch Intern Med; 1977 Oct; 137(10):1385-9. PubMed ID: 921420
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation.
Abu-Assi E; Otero-Raviña F; Allut Vidal G; Coutado Méndez A; Vaamonde Mosquera L; Sánchez Loureiro M; Caneda Villar MC; Fernández Villaverde JM; Maestro Saavedra FJ; González-Juanatey JR;
Int J Cardiol; 2013 Jun; 166(1):205-9. PubMed ID: 22104995
[TBL] [Abstract][Full Text] [Related]
19. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Lip GY; Rasmussen LH; Olsson SB; Zetterstrand S; Stahre C; Bylock A; Aunes-Jansson M; Eriksson U; Wåhlander K;
Thromb Res; 2011 Feb; 127(2):91-9. PubMed ID: 21172721
[TBL] [Abstract][Full Text] [Related]
20. [Individualized "minimal invasive" anticoagulation controlled with D-dimer-antigen testing - a concept].
Müller-Beissenhirtz W; Boschert H; Müller-Beissenhirtz H
Hamostaseologie; 2010 Nov; 30(4):190-3. PubMed ID: 21057711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
